相关实验视频
Updated: Jan 14, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
在阿尔法-1抗素缺乏相关的胰腺炎的耐火病例中Upadacitinib
Majda Chaoui1, Axel De Greef1,2, Liliane Marot3
1Dermatology, Cliniques Universitaires Saint-Luc, Brussels, BEL.
阿尔法-1抗素 (AAT) 缺乏可以导致泛炎,一种痛苦的皮肤疾病. 一种JAK抑制剂,upadacitinib,在患有AAT缺乏症相关的胰腺炎的患者中显示出显著的症状改善.
科学领域:
- 皮肤病学 皮肤病学
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔法-1抗素 (AAT) 缺乏症是一种罕见的遗传性疾病.
- 它可以导致肺气,肝硬化和胰腺炎.
- 与AAT缺乏相关的胰腺炎的治疗方法有限.
研究的目的:
- 报告与AAT缺乏相关的胰腺炎病例.
- 评估upadacitinib在治疗这种疾病中的疗效.
主要方法:
- 一名62岁的男性患者患有复发性泛炎和低AAT水平被治疗.
- 乌帕达西提尼布 (一种JAK1抑制剂) 服用了45毫克/天,持续了三个月.
- 监测临床反应和不良事件.
主要成果:
- 患者经历了发作频率的减少,疼痛,以及病变愈合的加速.
- 临床益处持续了治疗后三个月.
- 没有报告任何不良事件.
结论:
- 乌帕达西替尼 (upadacitinib) 显示出作为一种新型治疗方法的潜力,用于治疗与AAT缺乏相关的胰腺炎.
- 雅克抑制剂可能为这种罕见的疾病提供一种新的治疗选择.
- 需要进一步的研究来证实有效性和安全性.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis II: Clinical Manifestations and Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

